Medicines A–Z
P
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Plasma-derived concentrate of human coagulation factor XI (Hemoleven®) | ||
|
Plenvu® | ||
|
Plerixafor (Mozobil) | ||
 |
Pneumococcal polysaccharide vaccine (Pneumovax®II) | Protects from each of 23 types of pneumococcus |
|
|
Pneumococcal polysaccharude conjugate vaccine (adsorbed) (Prevenar 13®, Synflorix®) | For use in childhood immunisation programme. Protects against 13 strands of pneumococcus. Supported with PGD. |
|
|
Podophyllotoxin (Condyline) | ||
|
Podophyllum | ||
|
Polatuzumab (Polivy®) | ||
|
Poliomyelitis vaccines | ||
|
Polyfax nasal ointment |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
